Medicare GLP-1 Bridge Program (2026): $50 Copay, Eligibility, Start Date

For two decades, Medicare was legally barred from paying for weight-loss drugs — period. That changes on July 1, 2026. The Medicare GLP-1 Bridge is a time-limited federal demonstration that, for the first time, puts brand-name obesity GLP-1s within reach of Medicare beneficiaries at a fixed, predictable price. It is also confusing by design: it runs outside your Part D plan, has its own eligibility test and drug list, and expires at the end of 2027.

Direct answer: The Medicare GLP-1 Bridge program gives eligible Medicare Part D beneficiaries access to Wegovy (pen and tablets), Zepbound (KwikPen only), and Foundayo (Lilly's GLP-1 pill) for a flat $50 copay per monthly supply, from July 1, 2026 through December 31, 2027. Manufacturers supply the drugs to Medicare at a negotiated $245/month net price. To qualify you must be 18+, enrolled in an eligible Part D or Medicare Advantage drug plan, be using the GLP-1 for weight management, and meet one of three BMI tiers: BMI ≥35 alone, BMI ≥30 plus heart failure, uncontrolled hypertension, or stage 3a+ kidney disease, or BMI ≥27 plus pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease. There is nothing for you to sign up for — your doctor submits a prior authorization to a CMS central processor starting July 1.

If you take a GLP-1 for type 2 diabetes, sleep apnea, MASH, or cardiovascular risk, the Bridge is not for you — those indications already go through your regular Part D plan. See our companion guides on Medicare GLP-1 coverage overall and whether Medicare covers Zepbound.

Medicare GLP-1 Bridge Program at a Glance

What Is the Medicare GLP-1 Bridge?

The Bridge is a nationwide CMS demonstration — available in all states and territories — created under the agency's authority to test new payment approaches. It is explicitly not part of the Part D benefit: CMS adjudicates claims and pays pharmacies through a central processor, and Part D plans carry zero financial risk.

It exists because of a deal. On November 6, 2025, the White House announced most-favored-nation pricing agreements with Novo Nordisk and Eli Lilly: GLP-1s at roughly $350/month on the TrumpRx consumer platform, and — the piece that matters here — a $245/month Medicare price with a $50 beneficiary copay, in exchange for concessions including a multi-year tariff exemption. CMS formalized the program in a May 6, 2026 press release.

Medicare GLP-1 Bridge Eligibility: Who Qualifies

Your prescriber must attest that you are prescribed the drug to reduce excess body weight and maintain weight reduction, combined with ongoing lifestyle modification (structured nutrition and physical activity), that you are at least 18, and that you fall into one of three clinical tiers:

Two details people miss:

• BMI is measured at the time you first started GLP-1 therapy — not today. If you started Wegovy in 2024 at a BMI of 37 and you're at 34 now, you still qualify under Tier 1. CMS gives exactly this example.
• Your plan type matters. You must be in a standalone Part D plan (PDP) or a Medicare Advantage drug plan that is an HMO, HMO-POS, or local/regional PPO. Special Needs Plans, employer/union group waiver plans, and LI NET enrollees are eligible too. Not eligible: private fee-for-service plans, cost plans, and PACE — unless also enrolled in a standalone PDP. Dual-eligibles in qualifying plans can participate; TRICARE For Life only counts if you're also in an eligible Part D plan.

Who is excluded from the Bridge program

If your GLP-1 is prescribed for an indication Part D already covers, you must keep using your Part D plan — even if you also meet the BMI criteria. That means type 2 diabetes, moderate-to-severe obstructive sleep apnea, noncirrhotic MASH, and Wegovy's cardiovascular risk-reduction indication all stay inside Part D. The Bridge is exclusively for people whose only GLP-1 indication is weight itself — the group Medicare has always refused to cover. Full landscape in our Medicare GLP-1 coverage guide.

Which Drugs the Bridge Program Covers (and Which Formulations Don't)

Foundayo is the newest entry: the FDA approved Lilly's orforglipron pill on April 1, 2026 for adults with obesity (or overweight plus a weight-related condition), and CMS added it to the Bridge drug list on April 6, 2026. It produced about 12.4% average weight loss at the top dose in the ATTAIN-1 trial.

The Zepbound fine print matters: if you currently use Lilly's $299-$449 self-pay vials, those are not in the program — you'd switch to the multi-dose KwikPen to get the $50 price. Ozempic, Mounjaro, Rybelsus, and Saxenda are not in the Bridge at all.

Medicare Bridge Program GLP-1 Start Date and How to Enroll

The start date is July 1, 2026. Prior authorization requests will not be accepted or processed before that day. There is no beneficiary registration, no card, no opt-in. The process:

1. Talk to your prescriber about whether you meet the clinical criteria above.
2. Your provider submits a prior authorization — electronically (preferred) or by fax — to the CMS Central Processor, along with the prescription. Forms went up on the CMS Bridge webpage in June 2026.
3. CMS approves and notifies the pharmacy. The provider must attest you meet the BMI tier and are receiving lifestyle counseling.
4. You fill at the pharmacy and pay $50. The copay stays $50 every month, regardless of where you are in your Part D benefit year.

Questions go to 1-800-MEDICARE; CMS also runs a technical mailbox (glp1demo@cms.hhs.gov) for program questions.

What the $50 Copay Does NOT Do

Because the Bridge sits outside Part D, the $50 behaves differently than a normal copay:

• It does not count toward your Part D deductible.
• It does not count toward your true out-of-pocket costs (TrOOP) or the $2,100 2026 out-of-pocket cap.
• Low-Income Subsidy (Extra Help) does not apply — LIS beneficiaries pay the same $50 as everyone else, a point consumer advocates have flagged as the program's biggest equity gap.
• The $245 the government pays doesn't count toward your drug spend totals either.

How the GLP-1 Bridge Interacts With Part D Plans

Short version: it doesn't, by design. Your Part D plan keeps covering GLP-1s for diabetes, OSA, MASH, and cardiovascular indications under its normal formulary and prior-authorization rules — and CMS has warned plans it will monitor to make sure they don't quietly push members who belong in Part D over to the Bridge. If a plan denies a Part D-coverable GLP-1, the normal insurance appeal and exception process applies, not the Bridge.

Timeline: How the Medicare GLP-1 Bridge Came to Be

• Nov 6, 2025 — White House announces MFN pricing deals with Novo Nordisk and Eli Lilly; $245 Medicare price and $50 copay first promised.
• Jan-Apr 2026 — CMS designs the Bridge as a short-term ramp into the larger BALANCE model (a 5-year Part D + Medicaid demonstration).
• Apr 1, 2026 — FDA approves Foundayo; it joins the Bridge drug list days later.
• Apr 21, 2026 — The BALANCE model's Medicare Part D arm is indefinitely delayed after failing to hit the required 80% plan participation. The Bridge, originally ending December 31, 2026, is extended through December 31, 2027.
• May 6, 2026 — CMS issues its formal "Coming Soon" announcement.
• Jul 1, 2026 — Prior authorizations open; first $50 fills.

What happens after December 31, 2027 is genuinely unknown — Congress would need to change the law, or CMS would need a successor demonstration, for coverage to continue.

If You Don't Qualify (or Can't Wait Until July)

Manufacturer savings cards are off-limits to government-plan patients, but cash routes outside insurance are not. Lilly and Novo sell direct: Zepbound KwikPens run $299-$449/month and Wegovy starts around $149 (pill) to $349 (pen) self-pay — details in our Zepbound coupon and Wegovy coupon breakdowns, with the full price hierarchy in cheapest GLP-1.

On Medicare but locked out until July — or not eligible at all? Yücca telehealth — online evaluation, doctor-prescribed compounded Semaglutide+ or Tirzepatide+ filled by a licensed US pharmacy, from $146/month, no insurance involved. (Partner link: we may earn a commission, at no extra cost to you.)

Frequently Asked Questions

When does the Medicare GLP-1 Bridge program start? July 1, 2026. Prior authorization requests are not accepted before that date. The program runs through December 31, 2027.

How much will GLP-1s cost on the Medicare Bridge program? A flat $50 per monthly supply, in every month of the program, regardless of your Part D benefit phase. The government pays a negotiated $245/month net price to manufacturers.

Is Ozempic covered by the Medicare GLP-1 Bridge? No. Only Foundayo, Wegovy, and the Zepbound KwikPen are included. Ozempic and Mounjaro are diabetes-labeled drugs already covered by Part D for type 2 diabetes.

Do I need to sign up for the Medicare GLP-1 Bridge? No. There is no beneficiary enrollment. Your prescriber submits a prior authorization with a prescription to CMS's central processor starting July 1, 2026.

What BMI qualifies for the Medicare GLP-1 Bridge? BMI ≥35 alone; BMI ≥30 with heart failure (preserved ejection fraction), uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease — all measured at the time you started GLP-1 therapy.

Does the Bridge cover GLP-1s for diabetes or sleep apnea? No. Type 2 diabetes, OSA, MASH, and cardiovascular indications remain covered through your regular Part D plan, and people prescribed GLP-1s for those uses are excluded from the Bridge.

Last reviewed: June 13, 2026

Sources

• Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries — CMS Newsroom
• Medicare GLP-1 Bridge: Information for Medicare Beneficiaries — CMS
• What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge — KFF
• What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries — KFF
• Expanding Access to Weight Loss Medications: The Medicare GLP-1 Bridge Program — NCOA
• White House Strikes GLP-1 Pricing Deal With Lilly, Novo — BioSpace
• FDA approves Lilly's Foundayo (orforglipron) — PR Newswire
• Save on Wegovy — wegovy.com
• Zepbound Coverage and Savings — zepbound.lilly.com